HR 9661In Committee
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Introduced July 14, 2026
Summary
Timeline
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
See how this bill affects you
Enter your details to get a personalized impact estimate.
Check your impact